vasoactive intestinal peptide
Vasoactive intestinal peptide, also known as vasoactive intestinal polypeptide or VIP, is a peptide hormone that is vasoactive in the intestine. VIP is a peptide of 28 amino acid residues that belongs to a glucagon/secretin superfamily, the ligand of class II G protein–coupled receptors. VIP is produced in many tissues of vertebrates including the gut, pancreas, neocortex, and suprachiasmatic nuclei of the hypothalamus in the brain. VIP stimulates contractility in the heart, causes vasodilation, increases glycogenolysis, lowers arterial blood pressure and relaxes the smooth muscle of trachea, stomach and gallbladder. In humans, the vasoactive intestinal peptide is encoded by the VIP gene. — Wikipedia
Clinical trial activity
7 trials · 15 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 1998 (NCT00004494)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
SMILES
CC[C@@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(C)C)[C@@H](C)O)[C@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O- Mol. weight
- 3326.84 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVasoactive intestinal peptide ↗
- ChEMBLCHEMBL525028 ↗
Also known as
- vasoactive intestinal peptide
- vasoactive intestinal peptide
- vasoactive intestinal polypeptide
- vasoactive intestinal polypeptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06729606 | Phase 3 | Apr 20, 2021 | Department of Veteran Affairs, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), Medical Research Council, National Institute of Allergy and Infectious Diseases (NIAID), NeuroRx, Inc., Prevention and Early Treatment of Acute Lung Injury (PETAL), University of Copenhagen, University of Minnesota, University of New South Wales, University of Utah |
| NCT04260035 | N/A | Mar 1, 2020 | University of Copenhagen |
| NCT03989817 | N/A | Jun 14, 2019 | University of Copenhagen |
| NCT01471990 | N/A | May 1, 2011 | Cool Sorption Foundation of 1988, Lundbeck, University of Copenhagen |
| NCT00272896 | N/A | Oct 1, 2004 | University of Copenhagen |
| NCT00255320 | N/A | Dec 1, 2003 | University of Copenhagen |
| NCT00004494 | Phase 1 | Sep 1, 1998 | Food and Drug Administration, State University of New York, Stony Brook University |
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 6 | 5 | 2 | 2003 |
| Cool Sorption Foundation of 1988 | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2021 |
| Food and Drug Administration | Government | 1 | 0 | 1 | 1998 |
| International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Lundbeck | For profit | 1 | 0 | 1 | 2011 |
| Medical Research Council | Government | 1 | 0 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2021 |
| NeuroRx, Inc. | For profit | 1 | 0 | 1 | 2021 |
| Prevention and Early Treatment of Acute Lung Injury (PETAL) | Academic/Hospital | 1 | 0 | 1 | 2021 |
| State University of New York | Academic/Hospital | 1 | 0 | 1 | 1998 |
| Stony Brook University | Academic/Hospital | 1 | 1 | 1 | 1998 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of New South Wales | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2021 |